Last Updated: August 26, 2026

Details for Patent: 7,686,786


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,686,786
Title:Dial-down mechanism for wind-up pen
Abstract:The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction.
Inventor(s):Claus Schmidt Moller, Christian Peter Enggaard, Bo Radmer, Tom Hede Markussen
Assignee: Novo Nordisk AS
Application Number:US11/665,486
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,686,786
Patent Claim Types:
see list of patent claims
Delivery; Device;
Patent landscape, scope, and claims:

United States Patent 7,686,786 (Dial-Down Mechanism for Injection Devices): Claim Scope, Landscape, and US Exclusivity-Relevant Exposure

US Patent 7,686,786 is a mechanical IP asset centered on a dial-down (dose reduction) mechanism for an injection device that uses a torsion spring and a cam-and-key dose-setting interface. The core claim architecture is directed to the bidirectional straining and release of a torsion spring via dial-up and dial-down cams that engage corresponding keys on the same arm, with particular attention to cam track geometry and the possibility of multiple cams/keys per direction.

Below is a claim-by-claim scope dissection, followed by an actionable US patent landscape view focused on likely infringement entry points and freedom-to-operate (FTO) risk categories for competitors of injection pens and dial-up/dial-down dose settings.


What does US Patent 7,686,786 protect? Core invention and claim construction angles

Claim 1 is the independent claim and provides the practical infringement hook for most non-procedural disputes:

  1. Dial-down mechanism for an injection device using a torsion spring to assist injection.
  2. A dial-up cam (15) engaged by a dial-up key (11).
  3. A dial-down cam (16) engaged by a dial-down key (12).
  4. Bidirectional rotation of a dose setting member:
    • First rotation direction: dial-up cam + dial-up key cooperate to strain the torsion spring.
    • Second rotation direction (opposite to the first): dial-down cam + dial-down key cooperate to release the torsion spring.
  5. Same-track arrangement: dial-up and dial-down cams “form part of regions of the same track.”
  6. Same arm placement: dial-up and dial-down keys are both located on the same arm and are adapted to engage cams of the same track.

Practical claim construction: terms that drive scope

  • “Dial-down mechanism” is functional but constrained by the specified mechanical elements: cam and key, torsion spring straining/release, and same track/arm relationships.
  • “Form part of regions of the same track” is a specific structural limitation. It can be used to distinguish over designs with separate cam tracks, separate cam surfaces, or independent cam housings.
  • “Keys… located on the same arm” is another structural constraint that narrows scope. Designs with keys on different arms or separate linkages can avoid literal claim 1.

Bidirectional dose setting is the center of gravity

The claim’s mechanical logic is tied to reversible torsion spring management via opposing rotation directions. For competition analytics, that means:

  • If an alternative design uses reversible torsion loading but via different mechanical routing (e.g., ratchet + lever release, or a single cam with separate loading/unloading profiles not corresponding to “dial-up cam” and “dial-down cam” cooperating with distinct keys), literal fit is less likely.
  • If it uses reversible torsion loading but with different placement of keys (different arms) or separate cam tracks, the same-track/same-arm limitations can create defensibility.

How broad are the independent claim limits in US 7,686,786?

Claim 1 has both broad and narrow elements:

Broader aspects

  • “Injection device” and “handheld medication injection pen” appear in dependent claim scope (claim 10). Claim 1 itself is not limited to a specific pen architecture.
  • The claim does not require a particular dose magnitude method, specific actuation sequence, or specific dose setting resolution.

Narrowing aspects

Claim 1 is narrowed by:

  • Torsion spring assisting injection (not extension springs, magnets, purely mechanical plunger drive, etc.).
  • Two cam/key interactions tied to opposite rotational directions and torsion spring strain/release.
  • Same track relationship between dial-up and dial-down cam regions.
  • Same arm placement of both keys.

These “same track” and “same arm” constraints make the claim less likely to read onto generic torsion-spring injection pens that do not implement reversible dose setting via a combined cam-track with dual-direction key engagement.


What specific structural variations are covered by the dependent claims?

Is curved dial-up cam track geometry protected? (Claims 2 and 3)

  • Claim 2: dial-up cam (15) forms part of a curved track.
  • Claim 3: the curved track is circular, elliptical, or parabolic.

Scope effect: This adds geometric constraints for designs where dial-up cam region is specifically shaped as one of these conic/circular forms. If a competitor uses spline-like or multi-radius approximations that do not fall within circular/elliptical/parabolic characterization, literal coverage may be avoided, though doctrine-of-equivalents arguments can become fact-intensive.

Can the design include multiple dial-up cams and keys? (Claims 4 and 5)

  • Claim 4: comprises first and second dial-up cam.
  • Claim 5: comprises first and second dial-up key each adapted to engage the corresponding dial-up cam.

Scope effect: Covers scaling or redundancy architectures. If an alternative injection system uses multiple dial-up cam regions but keeps dial-down in a different arrangement (or uses different keys/links), coverage depends on whether claim 1 base limitations remain satisfied.

Is V-shaped dial-down cam track geometry protected? (Claim 6)

  • Claim 6: dial-down cam (16) forms part of a V-shaped track.

Scope effect: Again geometry-limited but strategically useful for enforcing against designs with sharp or V profile unload/release regions.

Can the design include multiple dial-down cams and keys? (Claims 7 and 8)

  • Claim 7: comprises first and second dial-down cam.
  • Claim 8: comprises first and second dial-down key each adapted to engage the corresponding dial-down cam.

Scope effect: Provides explicit coverage for multi-stage release or dual unloading profiles.

Is an injection pen covered specifically? (Claims 9 and 10)

  • Claim 9: medication delivery device with the dial-down mechanism of claim 1.
  • Claim 10: medication delivery device is a handheld medication injection pen.

Scope effect: Claim 1 can reach non-pen injection devices via claim 9; claim 10 focuses enforcement messaging on pen architectures, but only if claim 1 is satisfied.


How might a competitor design around US 7,686,786?

Design-around strategies map directly to claim 1 limitations:

1) Break “same track” relationship

  • Use separate cam tracks for dial-up and dial-down.
  • Use a single cam but with non-“region of the same track” architecture (depending on structural interpretation).
  • Use separate cam elements not forming “regions” of the same track.

2) Break “same arm” requirement

  • Place dial-up and dial-down keys on different arms or different moving parts.
  • Use a combined key but routed through different linkages so that “both located on the same arm” is not met.

3) Replace torsion spring loading/unloading mechanism

  • Use a ratchet/gear lock with a different energy storage element.
  • Use a cam that directly drives a plunger without torsion spring strain/release pairing as claimed.
  • Use tension springs, elastomer energy storage, or electromagnetic release instead of torsion spring strain/release.

4) Remove two-direction key/cam cooperation framing

  • Keep reversible torsion management but via a different cam-key architecture that does not match “dial-up cam… dial-up key” for strain and “dial-down cam… dial-down key” for release.

5) Avoid specific geometric claims in dependent coverage

Even if claim 1 is avoided, dependent claims can be attacked as well:

  • Avoid circular/elliptical/parabolic dial-up curved track characterizations.
  • Avoid V-shaped dial-down track.

What does the claim landscape likely look like around 7,686,786? (Mechanism families and risk buckets)

A torsion-spring, cam-and-key, dose setting mechanism is a typical injection pen mechanical theme. The landscape around US 7,686,786 generally clusters into families with overlapping concepts:

  1. Dose setting using a dial that rotates a dose setting member.
  2. Locking mechanisms that prevent unintended dose changes.
  3. Energy storage and delivery subsystems (often torsion springs).
  4. Cam surfaces with profiles that load energy in one direction and release it in the opposite or through a separate actuation motion.

But the specific enforcement wedge in 7,686,786 is the combination of:

  • dial-up vs dial-down cams, each engaged by corresponding keys,
  • with same track regions and same arm key placement,
  • controlling torsion spring strain/release from opposite rotation directions.

That combination can narrow the number of designs that fit literally, though equivalents litigation can broaden real risk.


What patentability or claim-strength issues are likely relevant?

Without prosecution history or file wrapper access in the prompt, the safest approach is to assess claim strength based on structural specificity:

  • Claim 1 is structurally detailed. That usually improves defensibility versus purely functional claims.
  • The “same track” and “same arm” limitations are likely to reduce prior art overlap where prior mechanisms separated cam tracks or used different key arms.
  • Dependent claims (curved track, conic geometry, V-shaped track) are narrower and likely harder to find in exactly matching form, improving relative defense if claim 1 is already found novel.

Enforcement strength depends on whether competitors’ mechanisms match the same-track/same-arm arrangement. If the market converged on different layouts, the practical enforcement window narrows.


What would an infringement analysis look like for a dial-up/dial-down injection pen?

A US infringement assessment typically breaks into:

  1. Identify the torsion spring assisting injection.
  2. Map the dose setting member rotation directions and correlate with:
    • dial-up rotation producing torsion strain.
    • dial-down rotation producing torsion release.
  3. Identify the dial-up cam and dial-down cam elements and their track relationship.
  4. Identify dial-up key and dial-down key elements and confirm they sit on the same arm.
  5. Confirm dial-up and dial-down cam regions are in regions of the same track.

If any of (3)–(5) are not met, claim 1 literal infringement is less likely.


When does US 7,686,786 lose exclusivity in the US?

No timing or Orange Book context is provided in the prompt, and mechanical device patents do not tie to NDA/BLA product exclusivity the way drug patents do. Also, a complete exclusivity timeline requires:

  • filing date,
  • earliest priority date,
  • any patent term adjustments or terminal disclaimers,
  • and (if relevant) whether any continuation affects term.

With the provided information alone, a complete exclusivity expiration analysis cannot be produced.


What Orange Book status applies to 7,686,786?

US 7,686,786 is a device mechanism patent as described by its claims (injection device components and dose setting mechanics). The prompt provides no drug NDA/BLA linkage. Without that linkage, a reliable Orange Book status statement cannot be produced from the information provided.


How strong is the patent estate for dial-down dose mechanisms?

Based strictly on the claim text provided:

  • The estate strength is claim-architecture dependent. Claim 1 is the core. Dependent claims add specific geometries and multi-cam variants.
  • The likely strong enforcement niche is against designs that:
    • use torsion spring energy storage,
    • use cam-and-key dose setting with reversible torsion strain/release,
    • implement dial-up and dial-down on the same track with keys on the same arm.

If the competitive field uses alternate layouts (separate cam tracks, different arms, different energy storage), enforceable overlap may be limited.


Key Takeaways

  • US 7,686,786 claim scope is anchored on bidirectional dial-up/dial-down rotation that strains and then releases a torsion spring via dial-up and dial-down cams engaged by dial-up and dial-down keys.
  • The most limiting, and most important, structural constraints are:
    • dial-up and dial-down cams are regions of the same track, and
    • both keys are located on the same arm.
  • Dependent claims add geometry and multiplicity coverage:
    • dial-up cam curved tracks (circular/elliptical/parabolic),
    • dial-down cam V-shaped track,
    • multi-cam variants (two dial-up cams/keys, two dial-down cams/keys).
  • For design-around, the highest-yield routes are breaking the same-track or same-arm relationships, or replacing torsion spring strain/release energy management.

FAQs

1) Does US 7,686,786 cover electronic or motor-driven dose adjustment?

The claim text is specific to a cam-and-key torsion spring straining/releasing mechanism tied to rotation of a dose setting member with dial-up/dial-down cams and keys, so purely electronic actuation without those mechanical elements would not match claim limitations as written.

2) Are separate dial-up and dial-down cam tracks a strong design-around?

Yes, because claim 1 requires the dial-up and dial-down cams to be regions of the same track.

3) Can a design with keys on different arms still infringe?

It can avoid claim 1 literal infringement if “both located on the same arm” is not met.

4) Do the geometric dependent claims control coverage if claim 1 is satisfied?

Dependent claim features can still matter for scope. If an accused device omits a dependent claim feature, that specific dependent claim is not infringed, but claim 1 coverage can still exist if its limitations are met.

5) Is the patent limited to injection pens only?

Claim 10 is limited to handheld injection pens, but claim 1 is broader as a dial-down mechanism for an injection device, and claim 9 covers medication delivery devices generally.


References

  1. United States Patent No. 7,686,786.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,686,786

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,686,786

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04077900Oct 21, 2004
PCT Information
PCT FiledOctober 20, 2005PCT Application Number:PCT/EP2005/011285
PCT Publication Date:May 04, 2006PCT Publication Number: WO2006/045526

International Family Members for US Patent 7,686,786

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria E444090 ⤷  Start Trial
Australia 2005298944 ⤷  Start Trial
Canada 2584760 ⤷  Start Trial
China 100571804 ⤷  Start Trial
China 101060874 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.